Thrivent Financial for Lutherans Invests $291,000 in Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Thrivent Financial for Lutherans acquired a new stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 40,909 shares of the biopharmaceutical company’s stock, valued at approximately $291,000. Thrivent Financial for Lutherans owned 0.05% of Portola Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in PTLA. William Blair Investment Management LLC lifted its position in Portola Pharmaceuticals by 37.9% in the first quarter. William Blair Investment Management LLC now owns 9,999,290 shares of the biopharmaceutical company’s stock worth $71,295,000 after purchasing an additional 2,750,218 shares during the period. Pictet Asset Management Ltd. boosted its stake in Portola Pharmaceuticals by 581.7% during the fourth quarter. Pictet Asset Management Ltd. now owns 864,456 shares of the biopharmaceutical company’s stock valued at $20,643,000 after buying an additional 737,656 shares in the last quarter. Norges Bank acquired a new position in Portola Pharmaceuticals during the fourth quarter worth about $15,126,000. Loomis Sayles & Co. L P bought a new stake in Portola Pharmaceuticals in the fourth quarter worth about $14,981,000. Finally, Deutsche Bank AG lifted its holdings in Portola Pharmaceuticals by 109.3% in the 1st quarter. Deutsche Bank AG now owns 1,035,573 shares of the biopharmaceutical company’s stock valued at $7,384,000 after acquiring an additional 540,766 shares during the last quarter. 98.68% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently commented on the stock. William Blair downgraded shares of Portola Pharmaceuticals to a “hold” rating in a report on Tuesday, May 5th. Royal Bank of Canada started coverage on Portola Pharmaceuticals in a report on Thursday, April 23rd. They issued an “outperform” rating and a $20.00 price target on the stock. Zacks Investment Research lowered Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 23rd. BidaskClub lowered Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, June 18th. Finally, Citigroup lowered Portola Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. Portola Pharmaceuticals has an average rating of “Hold” and an average target price of $26.50.

Shares of Portola Pharmaceuticals stock opened at $17.97 on Wednesday. The firm has a 50 day simple moving average of $17.90 and a 200 day simple moving average of $14.50. Portola Pharmaceuticals Inc has a fifty-two week low of $5.31 and a fifty-two week high of $31.73. The company has a debt-to-equity ratio of 4.77, a current ratio of 4.87 and a quick ratio of 4.82. The firm has a market cap of $1.41 billion, a P/E ratio of -4.77 and a beta of 2.25.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The firm had revenue of $26.40 million for the quarter, compared to analyst estimates of $33.88 million. Portola Pharmaceuticals had a negative net margin of 232.73% and a negative return on equity of 267.86%. The company’s revenue was up 18.9% compared to the same quarter last year. During the same period last year, the company earned ($1.02) EPS. On average, sell-side analysts expect that Portola Pharmaceuticals Inc will post -2.46 EPS for the current year.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Read More: Are all No-Load Funds Equal?

Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.